Median time estimates from MS onset to EDSS 3 were 13 y (95% CI 12–13) for European patients, 7 y (95% CI 4–12) for NAG1 and 15 y (95% CI 10–16) for NAG2 (Fig 1A). Here, GDF15 is linked to myeloid sarcoma.